Nephros, Inc. (NEPH) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $3.11. It has a SharesGrow Score of 76/100, indicating a strong investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NEPH = $3.65 (+17.6% from the current price, the stock appears undervalued).
Valuation: NEPH trades at a trailing Price-to-Earnings (P/E) of 25.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.22.
Financials: revenue is $19M, +25%/yr average growth. Net income is $1M, growing at +561.2%/yr. Net profit margin is 6.4% (thin). Gross margin is 61.1% (+13.7 pp trend).
Balance sheet: total debt is $1M against $10M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 4.06 (strong liquidity). Debt-to-assets is 7.8%. Total assets: $14M.
Analyst outlook: 4 / 4 analysts rate NEPH as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 85/100 (Pass), Growth 100/100 (Pass), Past 50/100 (Partial), Health 100/100 (Pass), Moat 50/100 (Partial), Future 100/100 (Pass), Income 45/100 (Partial).
